Table 2.
Clinical trials involving oncolytic viruses and pediatric tumors
| Virus | Completed studiesa | Current studiesa | Patient age range (years) | ClinicalTrials.gov Identifier | Referencesb |
|---|---|---|---|---|---|
| HSV-1(F) | |||||
| G207 | Phase I, recurrent malignant supratentorial brain tumors | 3–18 | NCT02457845 | ||
| HSV-1(17) | |||||
| HSV1716 (Seprehvir) | Phase I, recurrent gliomas Phase I, non-CNS solid tumors |
12–21 7–30 |
NCT02031965 NCT00931931 |
||
| Seneca Valley | |||||
| SVV-001 | Phase I, relapsed neuroblastoma, rhabdomyosarcoma, or other tumors with neuroendocrine features | 3–21 | NCT01048892 | 23 | |
| Reovirus | |||||
| Reolysin | Phase I, relapsed or refractory extracranial solid tumors | 3–20 | NCT01240538 | 40 | |
| Reolysin | Phase I, high-grade recurrent or refractory brain tumors | 10–21 | NCT02444546 | ||
| Vaccinia | |||||
| JX-594 (Pexa-Vex) | Phase I, refractory solid tumors; hepatoblastoma, neuroblastoma, Ewing sarcoma | 4–18 | NCT01169584 | 54 | |
Notes:
a
Blank areas indicate there are no completed studies, no current studies, and no clinical trials.
b
Blank areas indicate these are ongoing phase I studies that are not completed and the data are not yet published.
Abbreviations: HSV, herpes simplex virus; CNS, central nervous system; SVV, Seneca Valley virus.